Clinical and Laboratory Profile of Myasthenia Gravis in Children At Sohag University Hospitals

NCT ID: NCT06774937

Last Updated: 2025-01-14

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 20 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-02-01
• Study Completion Date: 2025-08-01

Brief Summary

This study includes clinical and laboratory studies of patients with Myathenia gravis at Sohag Neurology outpatient clinic of pediatric department

Detailed Description

All patients in this study were subjected to the followings:

(A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental history: neurological evaluation Family history. Mode of delivery

(B) Thorough clinical examination: General examination including general look, vital signs and anthropometric measurements.

Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) [36] detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:

1. Electrophysiological testing:

EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.

NCS: including repetitive nerve stimulation test (r NST)

2. laboratory studies: Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.

Thyroid function tests :

3. Imaging:

CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.

4. molecular studies (when possible).

Conditions

Myasthenia Gravis in Children

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

One group of patients againg one month to 16 years old with myasthenia gravis

Patients diagnosed with myasthenia gravis at the pediatric out patient clinic by clinical charactristics ,nerve study and laboratory data will be elligable for the study.

Inclusion Criteria:

• All patients from 1 month to 16 years confirmed diagnosis of myasthenia gravis by neurological and laboratory data.
• Care giver accept to participate in the study.

All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his

Intervention Type: DIAGNOSTIC_TEST

Thorough clinical examination:

1. General examination including general look, vital signs and anthropometric measurements.

2. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) [36] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:

1. Electrophysiological testing:

EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.

NCS: including repetitive nerve stimulation test (r NST)

2. laboratory studies:

• Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.
• Thyroid function tests :

3. Imaging:

• CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.

4. molecular studies (when possible).

EMG ,rNST,Ach R antibodies & thyroid function

Intervention Type: DIAGNOSTIC_TEST

C) Investigations:

1. Electrophysiological testing:

EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.

NCS: including repetitive nerve stimulation test (r NST)

2. laboratory studies:

• Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.
• Thyroid function tests :

3. Imaging:

• CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.

4. molecular studies (when possible).

Interventions

All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his

Thorough clinical examination:

1. General examination including general look, vital signs and anthropometric measurements.

2. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) [36] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:

1. Electrophysiological testing:

EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.

NCS: including repetitive nerve stimulation test (r NST)

2. laboratory studies:

• Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.
• Thyroid function tests :

3. Imaging:

• CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.

4. molecular studies (when possible).

Intervention Type: DIAGNOSTIC_TEST

EMG ,rNST,Ach R antibodies & thyroid function

C) Investigations:

1. Electrophysiological testing:

EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.

NCS: including repetitive nerve stimulation test (r NST)

2. laboratory studies:

• Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.
• Thyroid function tests :

3. Imaging:

• CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.

4. molecular studies (when possible).

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• All patients from 1 month to 16 years confirmed diagnosis of myasthenia gravis by neurological and laboratory data.

Care giver accept to participate in the study.

Exclusion Criteria

• Failure to obtain informed consent. Other neurological and neuromuscular disorders. Age above 16 years.

• Minimum Eligible Age: 1 Month
• Maximum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sohag University

OTHER

Sponsor Role: lead

Responsible Party

Menna Mohamed Sedik

Resident doctor of pediatric in ElHelal Hospital in Sohag

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Sohag University Hospital

Sohag, Sohag Governorate, Egypt

Sohag university

Sohag, , Egypt

Sohag university

Sohag, , Egypt

Countries

Egypt

Central Contacts

Menna Mohamed

Role: CONTACT

Mena011195@med.sohag.edu.eg

01011707915

Facility Contacts

Menna Mohamed Resident doctor of pediatric at El Helal hospital, Resident doctor of pediatric

Role: primary

Mena011195@med.sohag.edu.eg

01011707915 ext. 01011707915

Other Identifiers

Soh-Med-24-09-03MS

Identifier Type: -

Identifier Source: org_study_id